Tiger Brokers

Humanwell Healthcare Unit Secures US FDA Nod for Angina Drug

MT Newswires Live
Oct 09

Humanwell Healthcare's (SHA:600079) 80% owned subsidiary Yichang Humanwell Pharmaceutical has received approval from the US Food and Drug Administration for its Abbreviated New Drug Application for diltiazem hydrochloride tablets USP, according to a Shanghai bourse filing on Friday.

The prescription medication, intended to treat chronic stable angina and chest pain caused by coronary artery spasm, was approved in 30mg, 60mg, 90mg, and 120mg specifications.

Yichang Humanwell submitted the application in December 2025 following cumulative research and development investments totaling 12 million yuan.

Citing data from IQVIA, Humanwell said US market sales for diltiazem hydrochloride tablets reached about $12 million in 2025.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10